Oncotarget

Research Papers:

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study

Maria Grazia Cerrito _, Marco De Giorgi, Davide Pelizzoni, Sara Maria Bonomo, Nunzio Digiacomo, Arianna Scagliotti, Cristina Bugarin, Giuseppe Gaipa, Emanuela Grassilli, Marialuisa Lavitrano, Roberto Giovannoni, Paolo Bidoli and Marina Elena Cazzaniga

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:27448-27459. https://doi.org/10.18632/oncotarget.25422

Metrics: PDF 413 views  |   HTML 739 views  |   ?  


Abstract

Maria Grazia Cerrito1, Marco De Giorgi1, Davide Pelizzoni1,2, Sara Maria Bonomo1, Nunzio Digiacomo1,2, Arianna Scagliotti1, Cristina Bugarin4, Giuseppe Gaipa4, Emanuela Grassilli1, Marialuisa Lavitrano1, Roberto Giovannoni1, Paolo Bidoli1,2 and Marina Elena Cazzaniga1,2,3

1Department of Medicine and Surgery, University of Milano-Bicocca, Monza 20900, Italy

2Oncology Unit, ASST Monza, Monza 20900, Italy

3Phase 1 Research Centre, Monza 20900, Italy

4M.Tettamanti Research Center, Pediatric Clinic, University of Milano Bicocca, Monza 20900, Italy

Correspondence to:

Maria Grazia Cerrito, email: mariagrazia.cerrito@unimib.it

Keywords: triple-negative breast cancer; 5-fluorouracil; vinorelbine; metronomic combination; LC3A/B

Received: November 11, 2017     Accepted: May 01, 2018     Published: June 08, 2018

ABSTRACT

Triple Negative Breast Cancer (TNBC) is an aggressive neoplasia with median Overall Survival (OS) less than two years. Despite the availability of new drugs, the chance of survival of these patients did not increase. The combination of low doses of drugs in a metronomic schedule showed efficacy in clinical trials, exhibiting an anti-proliferative and anti-tumour activity. In Victor-2 study we recently evaluated a new metronomic combination (mCHT) of Capecitabine (CAPE) and Vinorelbine (VNR) in breast cancer patients showing a disease control rate with a median Progression-Free Survival (PFS) of 4.7 months in 28 TNBC patients.

Here in Victor-0 study, we examined the effect of mCHT vs standard (STD) schedule of administration of different combinations of 5-Fluorouracil (5FU), the active metabolite of CAPE, and VNR in TNBC cell lines MDA-MB-231 and BT-549. A significant anti-proliferative activity was observed in cells treated with metronomic vs STD administration of 5FU or VNR alone. Combination of the two drugs showed an additive inhibitor effect on cell growth in both cell lines. Moreover, after exposure of cells to 5FU and VNR under mCHT or conventional schedule of administration we also observed a downregulation of chemoresistance factor Bcl-2, changes in pro-apoptotic protein Bax and in cleaved effector caspase-3 and increased expression of LC3A/B autophagy protein.

Our results therefore suggest that molecular mechanisms implicated in apoptosis and autophagy as well as the cross-talk between these two forms of cell death in MDA-MB-231 and BT-549 cells treated with 5FU and VNR is dose- and schedule-dependent and provide some insights about the roles of autophagy and senescence in 5FU/VNR-induced cell death.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25422